SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that the Company will file its second quarter financial and operational results on August 14 and will host an investor conference call at 4:30 PM ET on Thursday, Aug. 15, to discuss earnings for the quarter ending June 30, 2019.
Medical Marijuana, Inc. CEO Dr. Stuart Titus and COO Blake Schroeder will provide updates on the financial and operational performance of the Company in the second quarter of 2019, share recent research and development progress, and discuss where the company is headed for the remainder of the year and in the future.
“We are excited to share our second quarter success and help shareholders understand the initiatives the Company is currently pursuing,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are optimistic that our transparency will provide confidence and clarity on where the future of Medical Marijuana, Inc. is headed.”
Interested parties have the opportunity to submit questions concerning the Company prior to the call to Stuart Smith at SmallCapVoice.com, Inc. via email: firstname.lastname@example.org by 12:00 PM ET on Wednesday, Aug. 14. Prior to the call, Mr. Smith will provide the Company with a list of submitted questions based on the relevance to the shareholder base and the question’s appropriateness concerning public disclosure rules.
To access the call:
Dial-In Number: 1-857-232-0157
Access Code: 422095
For those unable to attend the conference call, a replay will be available at https://www.smallcapvoice.com/tag/mjna/ shortly after the call has concluded.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.